LONDON, Oct 7 (Reuters) - Pfizer ( PFE ) on Monday won a

bid in a London court to invalidate two of GSK's patents

relating to a respiratory syncytial virus (RSV) vaccine.

The two pharmaceutical giants are among a number of

companies in competition for a vaccine for RSV, which typically

causes cold-like symptoms but is also a leading cause of

pneumonia in toddlers and older adults.